ABSTRACT : Background. Systemic administration of cannabidiol, a non-psychotomimetic component of Cannabis sativa, induces a rapid and maintained antidepressant effect in an animal model of depression. The medial prefrontal cortex, and more specifically the infralimbic cortex, have been associated to the fast antidepressant effect. However, the contribution of this important area to the effect of cannabidiol remains to be elucidated. Objectives. To analyze the effect of intra-infralimbic cannabidiol infusion on: (1) anxiety and depressive-like behaviors after 30 min and 24 h, and (2) the neuronal activation by c-Fos immunohistochemistry in the medial prefrontal cortex and the dorsal raphe nucleus in naïve and stressed animals.Results. Intr...
Rationale: Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like pro...
Resumen del póster presentado en el 27th ECNP Congress (European College of Neuropsychopharmacology)...
Background. Systemic administration of cannabidiol, a non-psychotomimetic component of Cannabis sati...
Resumen del trabajo presentado en la 19ª Reunión Anual de la Sociedad Española de Investigación sobr...
Rationale. Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
One outstanding clinic concern nowadays is the delay of the therapeutic effects of current antidepre...
One outstanding clinic concern nowadays is the delay of the therapeutic effects of current antidepre...
Trabajo presentado en Neuroscience 2018, celebrado en San Diego (Estados Unidos) del 03 al 07 de nov...
Objective: Cannabidiol is a chemical constituent from Cannabis sativa and it has multiple mechanisms...
Objective: Cannabidiol is a chemical constituent from Cannabis sativa and it has multiple mechanisms...
Background: Major depressive disorder (MDD) affects millions of people worldwide. While the exact pa...
Major Depression is a severe psychiatric condition with a still poorly understood etiology. In the l...
Resumen del póster presentado en Neuroscience 2014, organizado por la Society for Neuroscience, del ...
Rationale: Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
Rationale: Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like pro...
Resumen del póster presentado en el 27th ECNP Congress (European College of Neuropsychopharmacology)...
Background. Systemic administration of cannabidiol, a non-psychotomimetic component of Cannabis sati...
Resumen del trabajo presentado en la 19ª Reunión Anual de la Sociedad Española de Investigación sobr...
Rationale. Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
One outstanding clinic concern nowadays is the delay of the therapeutic effects of current antidepre...
One outstanding clinic concern nowadays is the delay of the therapeutic effects of current antidepre...
Trabajo presentado en Neuroscience 2018, celebrado en San Diego (Estados Unidos) del 03 al 07 de nov...
Objective: Cannabidiol is a chemical constituent from Cannabis sativa and it has multiple mechanisms...
Objective: Cannabidiol is a chemical constituent from Cannabis sativa and it has multiple mechanisms...
Background: Major depressive disorder (MDD) affects millions of people worldwide. While the exact pa...
Major Depression is a severe psychiatric condition with a still poorly understood etiology. In the l...
Resumen del póster presentado en Neuroscience 2014, organizado por la Society for Neuroscience, del ...
Rationale: Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
Rationale: Systemic administration of cannabidiol (CBD), a non-psychotomimetic component of Cannabis...
Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like pro...
Resumen del póster presentado en el 27th ECNP Congress (European College of Neuropsychopharmacology)...